MP28-19 SETTING THE BAR: A 4KSCORE OF 7.5% PROVIDES HIGH SENSITIVITY AND NEGATIVE PREDICTIVE VALUE FOR DETECTING AND RULING OUT SIGNIFICANT PROSTATE CANCER

• DOI: 10.1097/01.ju.0000557535.83589.c3
• Publication Date: 2019-04-24T05:40:57Z
• Authors: Amit Bhattu*; Yan Dong; Alexander Kong; Stephen Zappala; Dipen Parekh; Sanoj Punnen
• Keywords: Veterans Affairs; Prostate biopsy

You have accessJournal of UrologyProstate Cancer: Markers II (MP28)1 Apr 2019MP28-19 SETTING THE BAR: A 4KSCORE OF 7.5% PROVIDES HIGH SENSITIVITY AND NEGATIVE PREDICTIVE VALUE FOR DETECTING RULING OUT SIGNIFICANT PROSTATE CANCER Amit Bhattu*, Yan Dong, Alexander Kong, Stephen Zappala, Dipen Parekh, and Sanoj Punnen Bhattu*Amit Bhattu* More articles by this author , DongYan Dong KongAlexander Kong ZappalaStephen Zappala ParekhDipen Parekh PunnenSanoj View All Author Informationhttps://doi.org/10.1097/01.JU.0000557535.83589.c3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVES: Two independent prospective trials validated the 4Kscore test for predicting clinically significant cancer. However, they assessed 4kscore as a continuous score. We wanted illustrate use cut off deciding on need prostate biopsy using combined data from both trials. METHODS: This study pooled two multi-institutional One was conducted in 26 primarily community-based U.S. urology practices other at 8 Veterans Affairs Medical Centers. Men were 40-80 years old referred prostate. minimum 10-core required, phlebotomy done before ascertainment. The primary outcome presence Gleasons score ≥ 7 biopsy. performed exploratory analysis evaluate number biopsies avoided cancers detected entire cohort, various subgroups. RESULTS: included 1378 patients who had biopsy, which 1012 original validation 366 study. showed that 32.2% would been applying threshold sensitivity detecting Gleason cancer cut-off 94%, while negative predictive value ruling it out 95%. There no or higher missed when proceeding with Among less than 7.5%, findings benign 76.1% patients, revealed 6 19.1%, 3+4=7 3.4% 4+3=7 1.4% (Figure 1). Subgroup analyses PSA between 3-10ng/ml, African American non-African men difference risk those below 7.5%. CONCLUSIONS: is noninvasive biomarker helps facilitate decision-making. found allowed reduction high detection, aggressive Source Funding: OPKO diagnostics Miami, FL; Woburn, MA; Andover, FL© 2019 Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e411-e412 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand PDF downloadLoading ...